Trial Profile

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Oct 2026 According to an AB science media release, Clinical trial insurance obtained for the Phase 3 study in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) covering up to 39 euro million
29 Sep 2026 According to an AB science media release, the company plans to be able to resume this study in the fourth quarter of 2027
25 May 2026 According to an AB science media release, trial to initiate in in 2H26.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com